Home > Neurology > EAN 2019 > Multiple Sclerosis > Generalised EBV vaccine for progressive MS well-tolerated

Generalised EBV vaccine for progressive MS well-tolerated

Conference
EAN 2019
ATA188 is a pre-manufactured, unrelated donor Epstein-Barr virus (EBV)-targeted T cell immunotherapy for progressive MS. In a phase 1 study, ATA188 was well-tolerated by adults with progressive MS [1]. Previously, the same group had shown that treatment with an autologous EBV-targeted T cell immunotherapy may prevent progression in MS patients; 6 of 10 treated patients experienced both symptomatic and objective neurological improvement [2]. The study presented at the EAN evaluated safety and feasibility of monotherapy with ATA188 in EBV-seropositive adults with primary and secondary progressive MS. In this multicentre, open-label, single-arm, two-population, dose-escalation study, 4 dose cohorts, received 5.0x106, 1.0x107, 2.0x107, and 4.0x107 cells, respectively, on days 1, 8, and 15 in two cycles. Preliminary results of 6 participants in cohort 1 and 6 participants in cohort 2 who had received ≥1 dose were presented. Both doses were well-tolerated...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on